Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
Study to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments. štúdia fázy IIb/III, porovnávajúca účinnosť a bezpečnosť masitinibu v porovnaní s prvou líniou liečby , pri liečbe pacientov s relapsujúcou a remitentnou roztrúsenou sklerózou s neuspokojivou odpoveďou na prvú líniu liečby https://www.kusajili.fr:443/Trial/AasM-Gs3A0qCzd9Sb7KwWg%24study-to-compare-the-efficacy-andor-safety-of-masitinib-at-3-mgkgday-with-switch-to-45-then-to-6-mgkgday-to-interferon-beta-1a-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message